907544-17-6

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl (3R,4S)-4-amino-3-fluoropiperidine-1-carboxylate is used as a building block for the synthesis of various drug compounds. Its unique structure, including the fluorine atom and piperidine ring, makes it a valuable component in the development of fluorinated drug molecules with potential therapeutic applications.
Used in Drug Synthesis:
Tert-butyl (3R,4S)-4-amino-3-fluoropiperidine-1-carboxylate is used as a key intermediate in the creation of novel pharmaceuticals. Its presence in the molecular structure can enhance the pharmacological properties of the resulting drug compounds, making it a crucial component in drug discovery and development processes.
Used in Medicinal Chemistry Research:
Tert-butyl (3R,4S)-4-amino-3-fluoropiperidine-1-carboxylate is used as a research tool in medicinal chemistry. Its unique structural features allow scientists to explore its potential in the development of new drugs and therapeutic agents, contributing to the advancement of pharmaceutical sciences.

Upstream product

• 211108-48-4 tert-butyl 4-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 211108-50-8 tert-butyl-3-fluoro-4-oxopiperidine-1-carboxylate 
• 211108-52-0 (±)-cis-4-benzylamino-3-fluoropiperidine-1-carboxylic acid tert-butyl ester 
• 907572-28-5 tert-butyl-(3R,4S)-4-(benzylamino)-3-fluoro-piperidine-1-carboxylate 

Downstream Products

• 1174021-13-6 tert-butyl-(3R,4S)-4-({[(2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}amino)-3-fluoropiperidine-1-carboxylate 

Relevant academic research and scientific papers

Development of the Convergent, Kilogram-Scale Synthesis of an Antibacterial Clinical Candidate Using Enantioselective Hydrogenation

Early chemical development studies into the best way of assembling AZD9742, an antibacterial drug candidate, have involved swapping the order of two reductive aminations. The orthogonally functionalized aminopiperidine partner for these couplings is now enantioselectively synthesized using ruthenium-catalyzed asymmetric hydrogenation. The challenge of controlling defluorination through an appropriate catalyst choice has hitherto prevented this revised sequence from reaching its full potential. However, it is still shown to allow access to the active pharmaceutical ingredient in a stereochemically pure form and has been demonstrated on a multikilogram scale. The reductive aminations in both the original and revised sequences provided different scale-up challenges, and the solutions implemented are described.

PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2

The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these

Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3

Janus kinases (JAKs) regulate various inflammatory and immune responses and are targets for the treatment of inflammatory and immune diseases. As a novel class of immunomodulators targeting JAK3, 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives are promising candidates for treating such diseases. In chemical modification of lead compound 2, the substitution of a cycloalkyl ring for an N-cyanopyridylpiperidine in C4-position was effective for increasing JAK3 inhibitory activity. In addition, modulation of physical properties such as molecular lipophilicity and basicity was important for reducing human ether-a-go-go-related gene (hERG) inhibitory activity. Our optimization study gave compound 31, which exhibited potent JAK3 inhibitory activity as well as weak hERG inhibitory activity. In cellular assay, 31 exhibited potent immunomodulating effect on IL-2-stimulated T cell proliferation. In a pharmacokinetic study, good metabolic stability and oral bioavailability of 31 were achieved in rats, dogs, and monkeys. Further, 31 prolonged graft survival in an in vivo rat heterotopic cardiac transplant model.

Pyrrolamide DNA gyrase inhibitors: Optimization of antibacterial activity and efficacy

The pyrrolamides are a new class of antibacterial agents targeting DNA gyrase, an essential enzyme across bacterial species and inhibition results in the disruption of DNA synthesis and subsequently, cell death. The optimization of biochemical activity an

NEW COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein A, B, X, R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and t

CONDENSED PYRIDINE COMPOUND

The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention. More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).